Lupin Gets USFDA Nod for Myelodysplastic Syndrome Drug

Drug firm Lupin Thursday said it has received approval from the US health regulator to market Decitabine for injection, used for the treatment of myelodysplastic syndromes (MDS). The company has received an approval from the United States Food and Drug Administration (USFDA) to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement. Decitabine — the generic version of Otsuka’s Dacogen for Injection, 50 mg/vial — had annual sales of approximately USD 135.9 million in the US, it said. – Business Standard